| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 6.72▼ | 6.74▼ | 6.74▼ | 6.95▼ | 7.52▼ |
| MA10 | 6.74▼ | 6.73▼ | 6.73▼ | 7.25▼ | 8.02▼ |
| MA20 | 6.73▼ | 6.73▼ | 6.84▼ | 7.68▼ | 9.27▼ |
| MA50 | 6.74▼ | 6.94▼ | 7.18▼ | 8.25▼ | 9.55▼ |
| MA100 | 6.72▼ | 7.24▼ | 7.44▼ | 9.59▼ | 10.56▼ |
| MA200 | 6.83▼ | 7.51▼ | 7.96▼ | 9.57▼ | 11.82▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | 0.017▲ | 0.013▲ | -0.074▼ | -0.313▼ |
| RSI | 38.184▼ | 38.624▼ | 29.408▼ | 17.382▼ | 27.544▼ |
| STOCH | 30.000 | 64.158 | 59.652 | 3.511▼ | 9.540▼ |
| WILL %R | -100.000▼ | -28.571 | -59.184 | -87.261▼ | -96.108▼ |
| CCI | -146.667▼ | 26.537 | -44.098 | -170.347▼ | -144.944▼ |
|
Wednesday, October 08, 2025 06:09 AM
The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of ...
|
|
Wednesday, October 08, 2025 05:31 AM
GT Biopharma's Phase 1 trial of GTB-3650 progresses with early safety signals, immune activation, and plans to advance to higher dose cohorts into 2026.
|
|
Friday, September 19, 2025 04:00 AM
The New York Stock Exchange made a splash in February when it moved its NYSE Chicago medallion down south, rebranded as NYSE Texas. Since then, dozens of companies and exchange-traded products have ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/10/25 | 6.58 | 6.795 | 6.51 | 6.71 | 11,404,796 |
| 13/10/25 | 6.97 | 7.00 | 6.71 | 6.73 | 13,324,933 |
| 10/10/25 | 7.17 | 7.2556 | 6.825 | 6.83 | 13,445,752 |
| 09/10/25 | 7.36 | 7.36 | 7.12 | 7.13 | 9,663,891 |
| 08/10/25 | 7.41 | 7.49 | 7.32 | 7.34 | 7,211,982 |
| 07/10/25 | 7.58 | 7.5994 | 7.38 | 7.39 | 10,273,935 |
| 06/10/25 | 7.66 | 7.7101 | 7.53 | 7.56 | 8,854,120 |
| 03/10/25 | 7.54 | 7.99 | 7.54 | 7.72 | 11,809,531 |
| 02/10/25 | 7.55 | 7.65 | 7.51 | 7.53 | 8,097,752 |
| 01/10/25 | 7.51 | 7.69 | 7.48 | 7.54 | 8,447,795 |
|
|
||||
|
|
||||
|
|